Expert Opinion on Investigational Drugs

Papers
(The H4-Index of Expert Opinion on Investigational Drugs is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
PD-L1, TMB, and other potential predictors of response to immunotherapy for hepatocellular carcinoma: how can they assist drug clinical trials?74
Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer74
Biomarkers for breast cancer immunotherapy: PD-L1, TILs, and beyond70
Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases68
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials67
Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)66
Futibatinib, an investigational agent for the treatment of intrahepatic cholangiocarcinoma: evidence to date and future perspectives60
Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?51
Carbonic anhydrase inhibitors: an update on experimental agents for the treatment and imaging of hypoxic tumors51
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects50
Antisense oligonucleotide therapeutics in clinical trials for the treatment of inherited retinal diseases44
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success44
The role of Eph receptors in cancer and how to target them: novel approaches in cancer treatment41
Latest generation estrogen receptor degraders for the treatment of hormone receptor-positive breast cancer40
Developing DMD therapeutics: a review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies39
Risuteganib—a novel integrin inhibitor for the treatment of non-exudative (dry) age-related macular degeneration and diabetic macular edema38
Tislelizumab: an investigational anti-PD-1 antibody for the treatment of advanced non-small cell lung cancer (NSCLC)38
Oral Ibrexafungerp: an investigational agent for the treatment of vulvovaginal candidiasis38
Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas38
Novel emerging therapies in atherosclerosis targeting lipid metabolism36
Investigational IRAK-4 inhibitors for the treatment of rheumatoid arthritis36
Inhibition of Bruton´s tyrosine kinase as a novel therapeutic approach in multiple sclerosis36
ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease36
Pamrevlumab for the treatment of idiopathic pulmonary fibrosis36
Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson’s disease36
The anti-DKK1 antibody DKN-01 as an immunomodulatory combination partner for the treatment of cancer34
Anti-integrin therapy for retinovascular diseases32
Ladiratuzumab vedotin for metastatic triple negative cancer: preliminary results, key challenges, and clinical potential32
Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma32
New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis31
Givinostat: an emerging treatment for polycythemia vera31
Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–Positive Generalized Myasthenia Gravis31
BIO 300: a promising radiation countermeasure under advanced development for acute radiation syndrome and the delayed effects of acute radiation exposure31
0.043249130249023